Riskpilot← Back to searchSign inGet full accessIscaff Pharma AB
ABActiveOrg 5591209753Erik Dahlbergsgatan 11 AResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20170 employees
Revenue 2024
SEK 0
EBITDA margin
—
+29% vs 2023
Equity ratio
58.9%
Financial strength
Net profit 2024
SEK -4,2M
-183% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -1,1M | +29% |
| Net profit | SEK -4,2M | -183% |
| Total assets | SEK 3,2M | -60% |
| Equity | SEK 1,9M | -69% |
| Employees | 0 | — |
Legal name
Iscaff Pharma AB
Org number
5591209753
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
3 augusti 2017
Share capital
SEK 71 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas i förening av ledamöterna Firman tecknas av en av ledamöterna i förening med suppleanten
Company purpose
Föremålet för bolagets verksamhet är att bedriva verifierings- och utvecklingsarbete till kommersiell exploatering av ett nytt diagnostiskt test för cancerpatienter och en screeningplattform för läkemedelsindustrin och därmed förenlig verksamhet.
Address
Erik Dahlbergsgatan 11 A
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 359 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — | — | — |
| EBITDA | −76 | −374 | −179 | −657 | −1 776 | −1 604 | −1 145 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −3 101 |
| EBIT | −76 | −374 | −179 | −657 | −1 776 | −1 604 | −4 246 |
| Net financials | — | — | — | — | 4 | 128 | 67 |
| Profit before tax | −76 | −374 | −179 | −657 | −1 772 | −1 476 | −4 178 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −76 | −374 | −179 | −657 | −1 772 | −1 476 | −4 178 |
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Total assets | 703 | 836 | 4 470 | 3 674 | 8 237 | 7 863 | 3 167 |
| Equity | 274 | 399 | 4 024 | 3 366 | 7 520 | 6 044 | 1 866 |
| Long-term debt | 0 | 0 | 0 | 0 | 400 | 400 | 400 |
| Short-term debt | 429 | 437 | 446 | 307 | 317 | 1 420 | 901 |
| Total debt | 429 | 437 | 446 | 307 | 717 | 1 820 | 1 301 |
EBITDA margin
-114500000.0%
This company
15.8%
Market median
-724683644% vs market
20182024
Equity ratio
58.9%
This company
38.2%
Market median
+54% vs market
20182024
Return on equity
-223.9%
This company
18.4%
Market median
-1317% vs market
20182024
Net profit margin
-417800000.0%
This company
8.1%
Market median
-5158024791% vs market
20182024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20182024
Debt / equity
0.70×
This company
0.62×
Market median
+13% vs market
20182024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2017-08-01 – 2018-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
PJ Chief Executive Officer | Chief Executive Officer | 2021 | — | — |
FP Chief Auditor | Chief Auditor | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2022 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Deputy Board Member | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Chairman | 2020 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Iscaff Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Per Jonas Sigfrid Setterberg | Chief Executive Officer | 0 companies |
| Filip Patrik Laurin | Chief Auditor | 0 companies |
| Klementina Österberg | Deputy Board Member | 0 companies |
| Charlotta Elisabeth Lindvall Blom | Board of Directors | 0 companies |
| Anders Torbjörn Ståhlberg | Board of Directors | 0 companies |
| Jan Roland Pilebjer | Deputy Board Member | 0 companies |
| Göran Landberg | Board of Directors | 0 companies |
| Sara Johanna Kristina Malcus | Chairman | 0 companies |